FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
24/08/2026 12:13
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome Aug 24 (Reuters) - Regenxbio RGNX.O said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal MRI scans found abnormalities in five study participants.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics